EN | TR
E-ISSN: 2149-6447
Procedur Guideline for Lymphoscintigraphy and Sentinel Lymph Node in Breast Cancer
PDF
Cite
Share
Request
Guideline
VOLUME: 6 ISSUE: 3
P: 321-338
November 2020

Procedur Guideline for Lymphoscintigraphy and Sentinel Lymph Node in Breast Cancer

Nucl Med Semin 2020;6(3):321-338
DOI: 10.4274/nts.galenos.2020.0027
Gülin Uçmak 1
Bedriye Büşra Demirel 1
Murat Fani Bozkurt 2
İlknur Ak Sivrikoz 3
Zeynep Burak 4
Çiğdem Soydal 5
Emre Demirci 6
Tamer Atasever 7
1. Sağlık Bilimleri Üniversitesi, Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Nükleer Tıp Kliniği, Ankara, Türkiye
2. Hacettepe Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Ankara, Türkiye
3. Osmangazi Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Eskişehir, Türkiye
4. Ege Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İzmir, Türkiye
5. Ankara Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, Ankara, Türkiye
6. Yeditepe Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye
7. Medipol Üniversitesi Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

Sentinel lymph node (SLN) detection by lymphoscintigraphy (LS) and using intraoperative gamma probe is the mostly important prognostic factor in patients with breast cancer. Sentinel lymph node biopsy (SLNB) is a procedure that collaborated by nuclear medicine, surgical oncology and pathology medical disciplines, scientifically proven and established into routine. The aim of this guideline is to inform current knowledge about standart LS and SLN procedure and indications in breast cancer and to lead for nuclear medicine practitioners. The recommendations in this guide has been prepared by ‘Turkish Society of Nuclear Medine Oncology Task Group’ members.

References

1World Health Organization. Available from: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/
2Krag DN. Surgical resection and radiolocalization of the SLN in breast cancer using a gamma probe. Surg Oncol 1993;2:335-340.
3Giuliano AE, Kirgan D, Guenther JM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.
4Pijpers R, Meijer S, Hoekstra OS, et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloid albumin in breast cancer. J Nucl Med 1997;38:366-368.
5International Breast Cancer Consensus Conference. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg 2001;193:297-302.
6 Benson JR, Della Rovere GQ, Axilla Management Consensus Group. Management of the axilla in women with breast cancer. Lancet Oncol 2007;8:331-348.
7Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-466.
8Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
9Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 1993;2:303-308.
10Alazraki NP, Eshima D, Eshima LA, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 1997;27:55-67.
11Keshtgar MRS, Ell PJ. Sentinel lymph node detection and imaging. Eur J Nucl Med 1999;26:57-67.
12Mariani G, Moresco L, Viale G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med 2001;42:1198-1215.
13Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol 2006;7:983-990.
14Futamura M, Asano T, Kobayashi K, et al. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT. World J Surg Oncol 2015;13:49.
15Zhang X, Wu F, Han P. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Hell J Nucl Med 2014;17:177-183.
16Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging 2013;40:1932-1947.
17Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35:561-564.
18National Comprehensive Cancer Network. NCCN Clinical Breast Guidelines in Oncology. Breast Cancer. Version 2.2020. 2020. Available from: https://www.nccn.org/professionals/physician_gls/ pdf/breast.pdf.
19van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB. Axillary recurrence after a tumor-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008;34:1277-1284.
20Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881-888.
21Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg 2008;247:315-319.
22Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010;102:170.
23Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011;260:119-128.
24Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-7720.
25Karakatsanis A, Hersi AF, Pistiolis L, et al. SentiNot Trialists Group. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). Br J Surg 2019;106:720.
26Wärnberg F, Stigberg E, Obondo C, et al. Long-term outcome after retro-areolar versus peri-tumoral injection of Superparamagnetic Iron Oxide Nanoparticles (SPIO) for sentinel lymph node detection in breast cancer surgery. Ann Surg Oncol 2019;26:1247.
27Arslan G, Yilmaz C, Celik L, Çubuk R, Tasalı N. Unexpected finding on mammography and mrı due to accumulation of ıron oxide particles used for sentinel lymph node detection. Eur J Breast Health 2019;15:200-202.
28Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006;203:475-480.
29Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer.  Ann Surg Oncol 2014;21:2506-2511.
30Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging 2010;37:78-83.
31Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: Are there any really? World J Surg Oncol 2007;5:10.
32Cragan JD. Teratogen update: methylene blue. Teratolog. 1999;60:42-48.
33Lyman GH, Temin S, Edge SB, et al; American Society of Clinical Oncology Clinical Practice. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2014;32:1365-1383.
34Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral ınjection for location of the sentinel lymph node. Ann Surg 1999;229:860-865.
35McMasters KM, Wong SL, Martin RC,  et al. University of Louisville Breast Cancer Study Group. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001;233:676-687.
36Schrenk P, Wayand W. Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer. Lancet 2001;357:122.
37Knauer M, Konstantiniuk P, Haid A, et al. Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study. J Clin Oncol 2006;24:3374-3380.
38Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 1098122023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:1303-1310.
39Cortazar P, Kluetz PG. Neoadjuvant breast cancer therapy and drug development. Clin Adv Hematol Oncol  2015;13:755-761.
40Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009;250:558-566. 
41Classe J-M, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726-732.
42Tan VKM, Goh BKP, Fook-Chong S, Khin L-W, Wong W-K, Yong W-S. The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis. J Surg Oncol 2011;104:97-103. 
43Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol 2009;16:551-563. 
44Bi Z, Liu J, Chen P, et al. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Breast Cancer. 2019;26:373-377.
45Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;14:609-618.
46Zetterlund LH, Frisell J, Zouzos A, Axelsson, et al. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer. Breast Cancer Res Treat 2017;163:103-110.
47Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016;34:1072-1078.
48Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg 2016;263:802. 
49Wong SL, Chao C, Edwards MJ, et al. Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg 2001;67:522-526-528.
50Maaskant-Braat AJG, Voogd AC, Roumen RMH, Nieuwenhuijzen GAP. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2013;138:13-20.
51Poodt IGM, Vugts G, Schipper RJ, et al. Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. Sentinel Node and Recurrent Breast Cancer (SNARB) study group Br J Surg 2019;106:574.
52Rodriguez Fernandez J,Martella S, Trifirò G, et al. Sentinel node biopsy in patients with previous breast aesthetic surgery. Ann Surg Oncol 2009;16:989-992.
53Shimazu K, Tamaki Y, Taguchi T, et al. Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer. Ann Surg 2003;237:390.
54Doting MH, Jansen L, Nieweg OE, et al. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer 2000;88:2546.
55Heuts EM, van der Ent FW, von Meyenfeldt MF, Voogd AC.  Internal mammary lymph drainage and sentinel node biopsy in breast cancer - A study on 1008 patients. Eur J Surg Oncol 2009;35:252.
56Harlow S, Krag D, Weaver D, Ashikaga T. Extra-Axillary Sentinel Lymph Nodes in Breast Cancer. Breast Cancer 1999;6:159.
57Cody HS 3rd, Urban JA. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 1995;2:32-37.
58Shen J, Hunt KK, Mirza NQ, et al. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 2004;101:1330-1337.
59Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382-2387.
60Morita ET, Chang J, Leong SP. Principles and controversies in lymphoscintigraphy with emphasis on breast cancer. Surg Clin North Am 2000;80:1721-1739.
61Giuliano, AE, Jones, RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-2350.
62Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multi-center validation study. N Engl J Med 1998;339:941- 946.
63Martin 2nd RC, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multiinstitutional study. For the University of Louisville Breast Cancer Study Group. Surgery 2000;128:139.
64McMasters, KM, Wong SL, Chao C, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node (SLN) biopsy: a model for implementation of new surgical techniques. Ann. Surg 2001;234, 292-300.
65McCarter MD, Yeung H, Yeh S, Fey J, Borgen PI, Cody HS 3rd. Localization of the sentinel node in breast cancer: identical results with same-day and day-before isotope injection. Ann Surg Oncol 2001;8:682-686.
66Dodia N, El-Sharief D, Kirwan CC. The use of isotope injections in sentinel node biopsy for breast cancer: are the 1- and 2-day protocols equally effective? Springer Plus 2015;4:495.
67Wilhelm AJ, Mijnhout GS, Franssen EJF. Radiopharmaceuticals in sentinel lymph-node detection-an overview. Eur J Nucl Med 1999;26:S36-S42.
68Vera DR, Wallace AM, Hoh CK. A synthetic macromolecule forsentinel node detection: (99m)Tc-DTPA-mannosyl-dextran. J Nucl Med 2001;42:951-959.
69Bergqvist l, Strand SE, Persson BR. Particle sizing and biokinetics of interstitial lymphoscintigraphic agents. Semin Nucl Med 1983;13:9-19.
70Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics, Adv Drug Deliv Rev 1995;17:129-148.
71Moghimi SM, Bonnemain B. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. Adv Drug Deliv Rev 1999;37:295-312.
72Uren RF, Howman-Giles RB, Thompson JF. Regarding sentinel lymph node localization in early breast cancer, J Nucl Med 1999;40:1403-1406.
73Babiera GV, Delpassand ES, Breslin TM, et al. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. Clin Nucl Med 2005;30:11-15.
74Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [(99m)Tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann. Surg. Oncol 2013;20:2590-2599.
75Unkart JT, Wallace AM. Use of 99mTc-Tilmanocept as a Single Agent for Sentinel Lymph Node Identification in Breast Cancer: A Retrospective Pilot Study. J Nucl Med Technol 2017;45:181-184.
76Tokin CA, Cope FO, Metz WL, et al. The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the 99mTc-labeled nanocolloid human serum albumin standard of care. Clin Exp Metastasis 2012;29:681-686.
77Ahmed M, Purushotham AD, Horgan K, Klaase JM, Douek M. Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer. BJS 2015;102:169-181.
78Uren RF, Howman-Giles R, Chung DK, et al. SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. Breast 2012;21 480-486.
79Uçmak G, Sahiner I, Demirtas S, Efetürk H, Demirel BB. Sentinel lymph node detection in contralateral axilla at initial presentation of a breast cancer patient: case report. Molecular Imaging and Radionuclide Therapy 2015;24:90-93.
80Mudun A, Sanli Y, Ozmen V, et al. Comparison of different injection sites of radionuclide for sentinel lymph node detection in breast cancer: single institution experience. Clin Nucl Med 2008;33:262-267.
81Roumen RMH, Geuskens LM, Valkenburg JGH. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur Surg Oncol 1999;25:347-351.
82Stojadinovic A, Peoples GE, Jurgens JS, et al. Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymphnode mapping and biopsy for early breast cancer (PASSION-P trial): a double-blind, randomised controlled trial. Lancet Oncol 2009;10:849-854.
83Pelosi E, Bello M, Griors M, et al. Sentinel lymph node detection in patients with early-stage breast cancer: comparison of periareolar and subdermal/peritumoral injection techniques. J Nucl Med 2004;45:220-225.
84Noguchi M, Inokuchi M, Zen Y. Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol 2009;100:100-105.
85Gray RJ, Pockaj BA, RoarkeMC. Injection of 99mTc-labeled sulfur colloid the day before operation for breast cancer sentinel lymph node mapping is as successful as injection the day of operation. Am J Surg 2004;188:685-689.
86Alazraki NP, Styblo T, Grant SF, Cohen C, Larsen T, Aarsvold JN. Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma-detecting probe. Radiol Clin North Am 2001;39:947-956.
87Freebody J, Fernando S, Rossleigh MA. Triple-site radiotracer application in breast lymphoscintigraphy and sentinel node discordance. World J Nucl Med 2019;18:127-131.
88Mudun A, Aslay I, Aygen M, et al. Can preoperative lymphoscintigraphy be used as a guide in treatment planning of breast cancer? Clin Nucl Med 2001;26:405-411.
89Buscombe J, Paganelli G, Burak ZE, et al. European Association of Nuclear Medicine Oncology Committee and Dosimetry Committee. Sentinel node in breast cancer procedural guidelines. Eur J Nucl Med Mol Imaging 2007;34:2154-2159.
90Wang H, Heck K, Pruitt SK, et al. Impact of delayed lymphoscintigraphy for sentinel lymphnode biopsy for breast cancer. J Surg Oncol 2015;111:931-934.
91Mariani G, Bruselli L, Kuwert T, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010;37:1959-1985.
92Lerman H, Metser U, Lievshitz G, Sperber F, Shneebaum S, Even-Sapir E. Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT-CT. Eur J Nucl Med Mol Imaging 2006;33:329-337.
93Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med 2007;48:201-206.
94Vermeeren L, van der Ploeg IM, Valdes Olmos RA, et al. SPECT/CT for preoperative sentinel node localization. J Surg Oncol 2010;101:184-190.
95Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med 2003;33:205-218.
96Cody HS 31rd, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001;8:13-19.
97Starver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010;17:1854-1861.
98Rodier JF, VeltenM, WiltM, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol 2007;25:3664-3669.
99Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13:491-500.
100Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol 2017;22:11-17.
101Zada A, Peek MC, Ahmed M, et al. Meta-analysis of sentinel lymph node biopsy in breast cancer using the magnetic technique. Br J Surg 2016;103:1409-1419.
102Gkegkes ID, Iavazzo C. Contrast Enhanced Ultrasound (CEU) Using Microbubbles for Sentinel Lymph Node Biopsy in Breast Cancer: a Systematic Review. Acta Chir Belg 2015;115:212-218.
103Povoski SP, Olsen JO, Young DC, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006;13:1412-1421.
104Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L. Is the “10% rule” equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol 2008;15:2728-2733.
105Ban EJ, Lee JS, Koo JS, Park S, Kim SI, Park B-W. How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer 2011;14:296-300.
106Yi M, Meric-Bernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer 2008;113:30-37.
107Clough KB, Nasr R, Nos C, VieiraM, Inguenault C, Poulet B. New anatomical classification of the axilla with implications for sentinel node biopsy. Br J Surg 2010;97:1659-1665.
108Giammarile F, Schilling C, Gnanasegaran G, et al. The EANM practical guidelines for sentinel lymph node localisation in oral cavity squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46:623-637.
109Krishnamurthy S, Meric-Bernstam F, Lucci A, et al. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 2009;115:1555-1562.
110Langer I, Guller U, Berclaz G, et al. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Res Treat 2009;113:129-136.
111Vanderveen KA, Ramsamooj R, Bold RJ. A prospective, blinded trial of touch prep analysis versus frozen section for intraoperative evaluation of sentinel lymph nodes in breast cancer. Ann Surg Oncol 2008;15:2006-2011.
112Viale G, Dell’Orto P, Biasi MO, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg 2008;247:136-142.
113Patani N, Mokbel K. The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Res Treat 2009;114:393-402.
114Bernet L, Cano R, Martinez M, et al. Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method: a multicentric Spanish study. Histopathology 2011;58:863-869.
115Rousseau C, Classe JM, Campion L, et al. The impact of nonvisualization of sentinel nodes on lymphoscintigraphy in breast cancer. Ann Surg Oncol 2005;12:533-538.
116Kwee TC, Basu S, Torigian DA, Saboury B, Alavi A. Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: Evolving contribution of PET in this setting. Eur J Nucl Med Mol Imaging 2011;38:1353-1366.
117Morgan-Parkes JH. Metastases: Mechanisms, pathways, and cascades. AJR Am J Roentgenol 1995;164:1075-1082.
118Brenot-Rossi I, Houvenaeghel G, Jacquemier J, et al. Nonvisualization of axillary sentinel node during lymphoscintigraphy: Is there a pathologic significance in breast cancer? J Nucl Med 2003;44:1232-1237.
119Lo YF, Hsueh S, Ma SY, Chen SC, Chen MF. Clinical relevance of nonvisualized sentinel lymph nodes in unselected breast cancer patients during lymphoscintigraphy. Chang Gung Med J 2005;28:378-386.
120Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-933. 
121van Diest PJ, de Boer M, van Deurzen CHM, Tjan-Heijnen VCG. Micrometastases and isolated tumor cells in breast cancer are indeed associated with poorer outcome. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:e140; author reply e141-e142. 
122The American Society of Breast Surgeons. Consensus Guideline on the Management of the Axilla in Patients With Invasive/In-Situ Breast Cancer. Offical Statement, 2019.
123Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-575.
124 Mudun A. Radiation safety in intraoperative use of gamma probes in breast cancer. J Breast Health 2009;5:115-118.
125Waddington WA, Keshtgar MR, Taylor I, Lakhani SR, Short MD, Ell PJ. Radiation safety of the sentinel lymph node technique in breast cancer. Eur J Nucl Med 2000;27:377-391.
126Law M, Ma WH, Leung R, et al. Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a phantom study with SPECT/CT and ICRP-103 recommendations. Eur J Radiology 2012;81:e717-e720.
127Clarke RH, Bines W. Evolution of ICRP Recommendations 1977, 1990, 2007 - Publications 26 to 60 to 103. OECD NEA, No 6920, 2011. Avaialable from: http://www.oecd-nea.org/rp/reports/2011/nea6920-ICRPrecommendations.pdf.
128Law M, Cheng KC, Wu PM, Ho WY, Chow LW. Patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a study using a female humanoid phantom and thermoluminescent dosimeters. Br J Radiol 2003;76:818-823.
129ICRP Publication 84: pregnancy and medical radiation. Ann ICRP 2000;30:1-43.
130Pandit-Taskar NN, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from Tc-99m sulfur colloid lymphoscintigrapy and sentinel node localization in breast cancer patients. J Nucl Med 2006;47:1202-1208.
131ICRP Publication 106: radiation dose to patients from radiopharmaceuticals: a third amendment to ICRP publication 53. Ann ICRP 2008;38:1-197.
132ICRP Publication 60: 1990 recommendations of the International Commission on Radiological Protection. Ann ICRP 1991;21:1-201.
133Klausen TL, Chakera AH, Friis E, Rank F, Hesse B, Holm S. Radiation doses to staff involved in sentinel node operations for breast cancer. Clin Physiol Funct Imaging 2005;25:196-202.
134Glass EC, Basinski JE, Krasne DL, Giuliano AE. Radiation safety considerations for sentinel node techniques. Ann Surg Oncol 1999;6:10-11.
135IAEA. Nuclear medicine resources manual. Vienna: International Anatomic Energy Agency; 2006. p. 509-521.
136Nugent N, Hill AD, Casey M, et al. Safety guidelines for radiolocalised sentinel node resection. Ir J Med Sci 2001;170:236-238.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House